Print

Novo Nordisk A/S (NVO) Reports Positive Results From First Phase 3 Trial With Long-Acting Factor IX for Treatment of Hemophilia B  
5/17/2013 10:18:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BAGSVAERD, DENMARK--(Marketwired - May 17, 2013) - Novo Nordisk today announced the completion of paradigm™ 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. Paradigm™ 2 is a multi-centre, blinded trial evaluating the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in patients with haemophilia B.

Company announcement No 37 / 2013: http://hugin.info/2013/R/1702902/562797.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1702902]


Further information

Media:

Mike Rulis
+45 3079 3573
Email Contact

Ken Inchausti (US)
+1 609 514 8316
Email Contact

Investors:
Kasper Roseeuw Poulsen
+45 4442 4303
Email Contact

Frank Daniel Mersebach
+45 4442 0604
Email Contact

Lars Borup Jacobsen
+45 3075 3479
Email Contact

Jannick Lindegaard (US)
+1 609 786 4575
Email Contact



Help employers find you! Check out all the jobs and post your resume.

//-->